Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleSupplement

Evaluation of Prostate Cancer with 11C-Choline PET/CT for Treatment Planning, Response Assessment, and Prognosis

Francesco Ceci, Paolo Castellucci, Paola Mapelli, Elena Incerti, Maria Picchio and Stefano Fanti
Journal of Nuclear Medicine October 2016, 57 (Supplement 3) 49S-54S; DOI: https://doi.org/10.2967/jnumed.115.170126
Francesco Ceci
1Service of Nuclear Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paolo Castellucci
1Service of Nuclear Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paola Mapelli
2Service of Nuclear Medicine, IRCCS San Raffaele Scientific Institute, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elena Incerti
2Service of Nuclear Medicine, IRCCS San Raffaele Scientific Institute, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Picchio
2Service of Nuclear Medicine, IRCCS San Raffaele Scientific Institute, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefano Fanti
1Service of Nuclear Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    66-y-old patient with Gleason score of 4 + 4 and pT3aN0(0/12)Mx cancer. Initial PSA was 8 ng/mL. Patient was treated with RP. BCR (PSA, 0.4 ng/mL; PSA doubling time, 6 mo) occurred 12 mo after RP. (A) 11C-choline PET/CT (maximum-intensity-projection [MIP], CT, and fused images) showed single left common iliac lymph node (SUVmax, 4; diameter, 8 mm). Metastasis-directed S-RT was subsequently performed; PSA nadir was 0.08 ng/mL. (B) 11C-choline PET/CT performed 3 mo after S-RT (MIP, CT, and fused images) showed complete metabolic response.

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    70-y-old patient with Gleason score of 4 + 4 and pT3aN1(2/15)Mx cancer. Initial PSA was 21 ng/mL. Patient was treated with RP. BCR (PSA, 11 ng/mL; PSA doubling time, 4.1 mo) occurred 10 mo after external-beam radiotherapy (EBRT). (A) 11C-choline PET/CT (maximum-intensity-projection [MIP] and fused images) showed single osteoblastic lesion involving right ilium and pubis bones (SUVmax, 10). (B) Patient was referred for metastasis-directed EBRT; PSA response (PSA, 0.4 ng/mL) after treatment was confirmed by 11C-choline PET/CT performed 3 mo after EBRT (MIP and fused images).

  • FIGURE 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3.

    62-y-old patient with Gleason score of 4 + 4 and pT3b N1(8/24)Mx cancer. Initial PSA was 18 ng/mL. Patient was treated with RP. BCR occurred 8 mo after RP, and ADT was administered. After 26 mo, patient developed CRPC (PSA, 14 ng/mL; PSA doubling time, 3.2 mo). (A) 11C-choline PET/CT (maximum-intensity-projection [MIP] images) showed positive lymph nodes in paratracheal region and left supraclavicular lymph node, and docetaxel was administered. (B) Subsequent 11C-choline PET/CT (MIP images) showed progression of disease (in mediastinal lymph nodes and third left rib) despite PSA response (PSA, 10 ng/mL). Patient was given abiraterone; PSA response occurred after 6 mo (PSA, 4 ng/mL). (C) 11C-choline PET/CT (MIP images) showed response of mediastinal lymph nodes and rib but increased uptake in supraclavicular lymph node. (D) Patient was given metastasis-directed external-beam radiotherapy; PSA response (PSA, 1 ng/mL) and partial response on 11C-choline PET/CT (MIP images) occurred.

  • FIGURE 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 4.

    Additional images of same patient as in Figure 3. (A) Fused images of left supraclavicular lymph node before metastasis-directed external-beam radiotherapy (EBRT). (B) Fused images of left supraclavicular lymph node after metastasis-directed EBRT. 11C-choline uptake decreased after EBRT, but necrotic component of node enlarged after EBRT (arrows).

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 57 (Supplement 3)
Journal of Nuclear Medicine
Vol. 57, Issue Supplement 3
October 1, 2016
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Evaluation of Prostate Cancer with 11C-Choline PET/CT for Treatment Planning, Response Assessment, and Prognosis
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Evaluation of Prostate Cancer with 11C-Choline PET/CT for Treatment Planning, Response Assessment, and Prognosis
Francesco Ceci, Paolo Castellucci, Paola Mapelli, Elena Incerti, Maria Picchio, Stefano Fanti
Journal of Nuclear Medicine Oct 2016, 57 (Supplement 3) 49S-54S; DOI: 10.2967/jnumed.115.170126

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Evaluation of Prostate Cancer with 11C-Choline PET/CT for Treatment Planning, Response Assessment, and Prognosis
Francesco Ceci, Paolo Castellucci, Paola Mapelli, Elena Incerti, Maria Picchio, Stefano Fanti
Journal of Nuclear Medicine Oct 2016, 57 (Supplement 3) 49S-54S; DOI: 10.2967/jnumed.115.170126
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • USE OF CHOLINE PET/CT TO GUIDE METASTASIS-DIRECTED S-RT
    • USE OF CHOLINE PET/CT TO GUIDE METASTASIS-DIRECTED SALVAGE LYMPH NODE DISSECTION
    • USE OF CHOLINE PET/CT TO ASSESS RESPONSE TO SYSTEMIC THERAPIES
    • PROGNOSTIC VALUE OF CHOLINE PET/CT
    • CONCLUSION
    • DISCLOSURE
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • The Future of Nuclear Medicine as an Independent Specialty
  • 11C-Choline Pharmacokinetics in Recurrent Prostate Cancer
  • Radiotheranostics in Prostate Cancer: Introduction and Overview
  • Google Scholar

More in this TOC Section

  • Pathway to Approval of Innovative Radiopharmaceuticals in China
  • Recent Advances in Radiotracers Targeting Novel Cancer-Specific Biomarkers in China: A Brief Overview
  • Clinical Implementation of Total-Body PET in China
Show more Supplement

Similar Articles

Keywords

  • 11C-choline PET/CT
  • salvage radiotherapy
  • Salvage lymph node dissection
  • PET-guided therapies
  • metastasis-directed therapies
SNMMI

© 2025 SNMMI

Powered by HighWire